| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA1027: Tebentafusp for treating advanced uveal melanoma |
|
Medicine details |
|
| Medicine name | tebentafusp (Kimmtrak®) |
| Formulation | intravenous injection |
| Reference number | 3834 |
| Indication | Monotherapy for the treatment of human leukocyte antigen (HLA) A*02:01 positive adult patients with unresectable or metastatic uveal melanoma |
| Company | Immunocore Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 24/03/2022 |
| NICE guidance | |